Aquestive Therapeutics, Inc. (AQST) News
Filter AQST News Items
AQST News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
AQST News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest AQST News From Around the Web
Below are the latest news stories about AQUESTIVE THERAPEUTICS INC that investors may wish to consider to help them evaluate AQST as an investment opportunity.
Aquestive Therapeutics Gains FDA Orphan Drug Exclusivity for Pediatric Seizure TreatmentLibervant is the first orally administered rescue therapy for pediatric seizure clusters. |
Aquestive Therapeutics Receives U.S. FDA Orphan Drug Exclusivity for Libervant® (diazepam) Buccal Film in Pediatric Patients with Seizure Clusters Ages Two to FiveU.S. FDA Orphan Drug exclusivity provides seven years of market exclusivity for Libervant® (diazepam) Buccal Film in the United States for the treatment of seizure clusters in patients ages 2 to 5WARREN, N.J., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the U.S. Food |
Developer Of EpiPen Alternative Aquestive Stock Undervalued Despite Strong Clinical Data, Analyst Sees Huge UpsideCantor initiated coverage on Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company with five commercialized products. The company also collaborates with pharmaceutical companies to bring new molecules to market using its technologies, like PharmFilm. Aquestive is advancing a late-stage proprietary product candidate for severe allergic reactions, including anaphylaxis, and an earlier-stage epinephrine prodrug topical gel for various dermatology conditions. Cantor highlights that th |
Aquestive Therapeutics' (NASDAQ:AQST) investors will be pleased with their favorable 88% return over the last yearIt hasn't been the best quarter for Aquestive Therapeutics, Inc. ( NASDAQ:AQST ) shareholders, since the share price... |
Aquestive Therapeutics Announces Positive FDA Feedback and Reaffirms NDA Submission Guidance for Anaphylm™ (epinephrine) Sublingual FilmReaffirms New Drug Application (NDA) first quarter 2025 submission guidanceConfirms no additional adult clinical trials are necessary prior to NDA submission Commenced pediatric trial in the U.S. and Canada WARREN, N.J., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies (“Aquestive,” the “Company” or “we”), today announc |
Is Aquestive Therapeutics (AQST) the Best Multibagger Stock to Buy Heading into 2025?We recently published a list of 10 Best Multibagger Stocks To Buy Heading into 2025. In this article, we are going to take a look at where Aquestive Therapeutics, Inc. (NASDAQ:AQST) stands against other best multibagger stocks. November has been an eventful month so far for the market as the Fed cut rates by a quarter […] |
Aquestive Therapeutics to Participate in Two Upcoming Investor ConferencesWAQRREN, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today that the management team will participate in two upcoming investor conferences in November and December 2024 as follows: Jefferies London Annual Healthcare Conference: management will be available for 1x1 meeti |
Aquestive Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS LagsAquestive Therapeutics ( NASDAQ:AQST ) Third Quarter 2024 Results Key Financial Results Revenue: US$13.5m (up 4.2% from... |
Aquestive Therapeutics Inc (AQST) Q3 2024 Earnings Call Highlights: Navigating Growth Amidst ...Despite a revenue increase, Aquestive Therapeutics Inc (AQST) faces challenges with increased losses and expenses while advancing its promising product pipeline. |
Aquestive Therapeutics (AQST) Q3 Earnings: How Key Metrics Compare to Wall Street EstimatesAlthough the revenue and EPS for Aquestive Therapeutics (AQST) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. |